GLP-1 Shot vs Pill: Which Is More Effective for Weight Loss?

GLP-1 medications from $147/mo. Free eligibility check.

Quick answer: shot or pill?

For maximum weight loss, GLP-1 shots are superior. Injectable semaglutide (Wegovy) produces ~15% weight loss and tirzepatide (Zepbound) ~22.5%. Oral options are improving — Foundayo (orforglipron, 2026) achieves ~12-13% — but injections still lead in effectiveness.

For cost-effectiveness, compounded injectable semaglutide ($147/mo) offers the best value.

All GLP-1 options compared

Why shots work better than pills

Bioavailability: the key difference

Bioavailability means how much of the medication reaches your bloodstream. This is the single biggest factor explaining why GLP-1 shots outperform pills:

• Injectable semaglutide: ~89% bioavailability — nearly all the medication works
• Oral semaglutide (Rybelsus): ~1% bioavailability — 99% is destroyed by stomach acid
• Oral orforglipron (Foundayo): ~30-40% bioavailability — small molecule, not a peptide, survives digestion better

Rybelsus compensates for low bioavailability with a much larger dose (14 mg oral vs 2.4 mg injectable), but still delivers less active medication to GLP-1 receptors.

Dosing convenience

Side effects comparison

Side effects for both forms are generally mild and improve after 2-4 weeks as the body adjusts. Following the titration schedule is the most effective way to minimize side effects regardless of form.

Who should choose the shot?

• People who want maximum weight loss (15-22%)
• Those who prefer once-weekly dosing over daily pills
• People looking for the most cost-effective option (compounded from $147/mo)
• Those comfortable with self-injection (thin needle, minimal pain)
• People with GERD or stomach issues (oral GLP-1 can worsen reflux)

Who should choose the pill?

• People with severe needle phobia who cannot self-inject
• Frequent travelers who want to skip cooling cases and needles
• Those who prefer the simplicity of a daily pill
• People who want Foundayo at $149/mo (competitive with compounded injectables)
• Patients who need room-temperature storage

The future: oral GLP-1s are improving fast

The gap between shots and pills is closing. Oral orforglipron (Foundayo, 2026) already achieves ~12-13% weight loss — close to injectable semaglutide's 15%. More oral options are in development:

• Oral semaglutide 50mg: Higher-dose version in Phase 3 trials, may match injectable efficacy
• Danuglipron (Pfizer): Oral GLP-1 in development
• Oral tirzepatide: Eli Lilly is developing an oral version of their most effective drug

Bottom line

For maximum weight loss today, GLP-1 injections are the clear winner (15-22% vs 5-13% for pills). Compounded injectable semaglutide from $147/month offers the best value. However, if needle phobia or travel convenience is a priority, oral Foundayo at ~$149/month is a strong alternative with ~12-13% weight loss. Discuss both options with your provider to find the best fit.